Neurocrine starts Phase 2 trial of NBI-567 for Alzheimer's disease

October 20, 2026 8:30 AM

Neurocrine Biosciences (Nasdaq: NBIX) has initiated a Phase 2 clinical study of investigational compound NBI-1117567 (NBI-567) in adults with mild ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found